Drug-coated balloon for early recurrent arteriovenous fistula dysfunction
The Journal of Vascular Access · 2024
DOI: 10.1177/11297298231166426 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Vascular Access, 2024. Verfasst von Chun-Hsien Hsin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Linkou. Hauptthemen laut MEDLINE: Arteriovenous Shunt, Surgical, Vascular Patency, Coated Materials, Biocompatible, Angioplasty, Balloon. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
Objective
To report the efficacy and safety of a drug-coated balloon (Ranger, Boston Scientific) in patients with dysfunctional autogenous arteriovenous fistula.
Methods
In this investigator-initiated, prospective observational cohort study, 25 participants with dysfunctional arteriovenous fistula were enrolled from January 2018 to June 2019. The drug-coated balloon was applied after successful vessel preparation by high-pressure balloon angioplasty. The primary endpoint was the target lesion primary patency rate at 6 months. The secondary outcome included anatomical and clinical success rate, postoperative major adverse events within 30 days, and the target lesion primary patency rate at 12 months. Statistical analysis of the data was performed. The χ test or Fisher’s exact test was used for analyzing categorical variables, and continuous variables were analyzed using Student’s t-test. Also, Kaplan-Meier analysis was used to evaluate the target lesion primary patency days with the log-rank test.
Results
At 6 months, the target lesion primary patency rate was 68% in the drug-coated balloon treatment group. The anatomical and clinical success rates were 100%. One patient had thrombosed access 10 days after the index procedure, and two died of cardiovascular events 4 months after the operation. Subgroup analysis showed that the early recurrent stenosis group had non-inferior mean drug-coated balloon primary patency days (less than 90 days after prior percutaneous angioplasty, n = 10) compared with the late recurrence group (prior PTA patency days more than 90 days, n = 10), 179.3 ± 102.9 versus 257.1 ± 71 days ( p = 0.153). DCB angioplasty had significant improvement in primary patency days for early recurrent stenosis (67.7 ± 19.3 vs 179.3 ± 102.9, p < 0.001).
Conclusions
The results demonstrated the appliance of Ranger DCB in stenotic AVFs is a safe and effective treatment modality, especially for early recurrent AVF stenosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Linkou.
ORCID-Profile: Chun-Hsien Hsin, Po-Jen Ko
Förderung
- Boston Scientific Corporation
Zitieren
APA
Hsin, C. H., Yang, H. T., Feng, P. C., Su, T. W., Yu, S. Y., & Ko, P. J. (2024). Drug-coated balloon for early recurrent arteriovenous fistula dysfunction. The Journal of Vascular Access. https://doi.org/10.1177/11297298231166426
Vancouver
Hsin CH, Yang HT, Feng PC, Su TW, Yu SY, Ko PJ. Drug-coated balloon for early recurrent arteriovenous fistula dysfunction. The Journal of Vascular Access. 2024. doi:10.1177/11297298231166426
BibTeX
@article{Hsin2024,
author = {Hsin, Chun-Hsien and Yang, Hsuan-Tzu and Feng, Pin-Chao and Su, Ta-Wei and Yu, Sheng-Yueh and Ko, Po-Jen},
title = {Drug-coated balloon for early recurrent arteriovenous fistula dysfunction},
journal = {The Journal of Vascular Access},
year = {2024},
doi = {10.1177/11297298231166426}
}
EUVIMED